Home » Stocks » DCTH

Delcath Systems, Inc. (DCTH)

Stock Price: $16.07 USD -0.95 (-5.58%)
Updated Jan 15, 2021 4:00 PM EST - Market closed
After-hours: $16.00 -0.07 (-0.44%) Jan 15, 7:59 PM
Market Cap 93.14M
Revenue (ttm) 1.66M
Net Income (ttm) -4.69M
Shares Out 4.29M
EPS (ttm) -2.91
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 15
Last Price $16.07
Previous Close $17.02
Change ($) -0.95
Change (%) -5.58%
Day's Open 16.88
Day's Range 15.58 - 16.93
Day's Volume 149,868
52-Week Range 7.31 - 18.69

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 6 days ago

NEW YORK, Jan. 11, 2021 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq:  DCTH   ), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the ...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the live...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the live...

GlobeNewsWire - 1 month ago

NEW YORK, Dec. 07, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, to...

Seeking Alpha - 2 months ago

Delcath Systems, Inc. (DCTH) CEO Gerard Michel on Q3 2020 Results - Earnings Call Transcript

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, toda...

GlobeNewsWire - 2 months ago

NEW YORK, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of primary and metastatic cancers, toda...

GlobeNewsWire - 2 months ago

Overall Response Rate of 72% observed in patients with metastases confined to the liver Overall Response Rate of 72% observed in patients with metastases confined to the liver

GlobeNewsWire - 3 months ago

NEW YORK, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH) today announced that the Board of Directors appointed Gerard Michel as Chief Executive Officer, effective Octob...

Seeking Alpha - 3 months ago

Safety data of early part of FOCUS trial have been publicly disseminated.

GlobeNewsWire - 4 months ago

NEW YORK, Sept. 10, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cance...

GuruFocus - 4 months ago

Wall Street recommends to buy shares of SenesTech Inc (NASDAQ:SNES) and Delcath Systems Inc (NASDAQ:DCTH), even though these two stocks have disappointed so much over the prior 52 weeks throug...

Other stocks mentioned: SNES
GlobeNewsWire - 4 months ago

NEW YORK, Aug. 25, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancer...

Seeking Alpha - 5 months ago

Delcath Systems, Inc. (DCTH) CEO John Purpura on Q2 2020 Results - Earnings Call Transcript

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 06, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancer...

GlobeNewsWire - 5 months ago

NEW YORK, Aug. 03, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancer...

GlobeNewsWire - 7 months ago

NEW YORK, May 26, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers...

GlobeNewsWire - 8 months ago

Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020

GlobeNewsWire - 8 months ago

NEW YORK, May 05, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liv...

GlobeNewsWire - 8 months ago

NEW YORK, May 01, 2020 (GLOBE NEWSWIRE) -- Delcath Systems, Inc. (OTCQB:DCTH  NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers...

About DCTH

Delcath Systems, an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT... [Read more...]

Industry
Medical Devices
Founded
1988
CEO
Jennifer Simpson
Employees
33
Stock Exchange
NASDAQ
Ticker Symbol
DCTH
Full Company Profile

Financial Performance

In 2019, DCTH's revenue was $1.58 million, a decrease of -53.62% compared to the previous year's $3.41 million. Losses were -$8.88 million, -53.81% less than in 2018.

Financial Statements

Analyst Forecasts

The average 12-month stock price forecast for DCTH is 20.67, which is an increase of 28.62% from the latest price.

Price Target
$20.67
(28.62% upside)